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Abstract
Background: There is need for locally-derived age-specific clinical laboratory reference ranges of healthy Africans in sub-
Saharan Africa. Reference values from North American and European populations are being used for African subjects
despite previous studies showing significant differences. Our aim was to establish clinical laboratory reference values for
African adolescents and young adults that can be used in clinical trials and for patient management.
Methods and Findings: A panel of 298, HIV-seronegative individuals aged 13–34 years was randomly selected from
participants in two population-based cross-sectional surveys assessing HIV prevalence and other sexually transmitted
infections in western Kenya. The adolescent (,18 years)-to-adults ($18 years) ratio and the male-to-female ratio was 1:1.
Median and 95% reference ranges were calculated for immunohematological and biochemistry values. Compared with U.S-
derived reference ranges, we detected lower hemoglobin (HB), hematocrit (HCT), red blood cells (RBC), mean corpuscular
volume (MCV), neutrophil, glucose, and blood urea nitrogen values but elevated eosinophil and total bilirubin values.
Significant gender variation was observed in hematological parameters in addition to T-bilirubin and creatinine indices in all
age groups, AST in the younger and neutrophil, platelet and CD4 indices among the older age group. Age variation was also
observed, mainly in hematological parameters among males. Applying U.S. NIH Division of AIDS (DAIDS) toxicity grading to
our results, 40% of otherwise healthy study participants were classified as having an abnormal laboratory parameter (grade
1–4) which would exclude them from participating in clinical trials.
Conclusion: Hematological and biochemistry reference values from African population differ from those derived from a
North American population, showing the need to develop region-specific reference values. Our data also show variations in
hematological indices between adolescent and adult males which should be considered when developing reference ranges.
This study provides the first locally-derived clinical laboratory reference ranges for adolescents and young adults in western
Kenya.
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Introduction
An increasing number of clinical trials taking place in sub-
Saharan Africa are seeking to identify safe and effective prevention
and treatment strategies to combat the heavy burden of infectious
diseases in this region [1,2]. Africa is disproportionately affected by
numerous viral, parasitic and bacterial diseases, including: 66% of
the global HIV/AIDS infections [3,4], 31% of the tuberculosis
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Saharan Africa need accurate clinical laboratory reference ranges
for appropriate screening of volunteers in clinical trials, monitor-
ing disease progression, and evaluating possible clinical trial-
associated toxicity and adverse events. Traditionally, normal
ranges for clinical laboratory values have been obtained mainly
from European and North American populations [2]. However,
differences are known to occur between normal Africans values
with those of North Americans and Europeans [6]. For example,
African populations are reported to have lower hemoglobin (HB),
red blood cells (RBCs), hematocrit (HCT), mean corpuscular
volumes (MCV), platelets and neutrophils, and higher monocyte
and eosinophil levels than their Western counterparts [6–9].
Moreover, there are variations in indices between different African
ethnic groups [9–12]. Factors such as genetics, dietary patterns,
gender, age, ethnic origin and environmental pathogens are
known to influence hematological and immunologic indices [13–
16]. Thus, the use of normal laboratory values derived from
external populations could produce selection bias leading to
exclusions of otherwise healthy volunteers in clinical trials,
misclassification of adverse events, and a framework for allowing
incorrect patient management in routine clinical care.
Besides the relevant utility of laboratory reference values for
clinical trials, such values are also important in routine health
assessment, particularly for screening of anemia, blood disorders
and diseases of the immune system. Of particular importance is
the use of these indices as surrogate markers for disease
progression and response to anti-retroviral therapy in HIV-
infected individuals [17]. Decisions to initiate, monitor, or change
antiretroviral therapy (ART) regimens are determined using
CD4+ T-lymphocyte cell (CD4) counts, while drug toxicity is
monitored using liver function tests (LFT) and renal function tests
(RFT), and complete blood counts (CBC) [18,19]. Due to
differences in these parameters between Western and African
populations, it is necessary to develop a range of local values for
these indices. In addition, differences in hematological and
lymphocyte indices between age groups also suggests the need to
develop age-specific reference ranges [8,14,15,20]. However,
information about reference values based on age groups is limited
for the Africa populace [6,21–23].
The aim of our study was to generate normal ranges of
laboratory values for blood chemistry, hematologic and immuno-
logic indices of healthy, HIV-negative females and males aged 13
to 34 years. We also determined gender and age variations in these
indicators. In addition, we compared our normal range values
with those previously reported from the African continent and
with North American-derived reference ranges from the Massa-
chusetts General Hospital [24] and the U.S. NIH Division of
AIDS (DAIDS) which are currently used to measure the severity of
adverse events in most clinical research studies [25].
Methods
Study population and subject recruitment
Between October 2003 and May 2005, two baseline cross-
sectional surveys were conducted by the US Centers for Disease
Control and Prevention (CDC) in collaboration with the Kenya
Medical Research Institute (KEMRI), the Institute of Tropical
Medicine in Antwerp (ITM), and the London School of Hygiene
and Tropical Medicine (LSHTM) in two rural communities on the
shores of Lake Victoria about 50 kilometers from Kisumu city in
western Kenya. The aim of the surveys was to estimate the
prevalence of HIV and sexually transmitted infections (STIs), and
associated risk factors, in preparation for a future biomedical HIV-
prevention intervention trial in rural western Kenya [26].
The majority of the inhabitants in this area are of Luo ethnic
group (98%). This region is ,3700 feet above sea level, has
perennial malaria transmission and both endemic schistosomiasis
and helminthic infections [27,28]. KEMRI/CDC has a long-
standing presence in this region through malaria research and a
comprehensive health and demographic surveillance system
(HDSS) covering approximately 220,000 residents [29].
The first survey in Asembo, Rarieda District, enrolled 1822
individuals aged 13 to 34 years via stratified random sampling by
gender and age-group; the second survey in the Gem Siaya
District used cluster sampling (villages) to enroll 912 individuals
aged 15 to 34 years. In both surveys, all participants received a
review of medical history, a physical examination, testing for HIV
and pregnancy (for females), and treatment for medical illnesses
and STI that were diagnosed [26]. Participants were included in
the two surveys if permanent residents of the area, between 13 and
34 years of age and able to provide informed consent or assent in
case of minors.
From the two surveys, approximately 11% of blood samples from
clinically healthy participants in each of the two districts were
selected to generate reference ranges in this study. Participants were
excluded if HIV-seropositive, pregnant, exhibiting febrile symptoms
and on medication. Selection of participants from the two surveys
involved stratified systematic sampling with strata comprising of
males and females and further sub-stratification by age (i.e.
adolescents; ,18 vs. adults; $18) to include an approximate equal
number of participants in each sub-strata. After stratification
samples from participants who met the study eligibility criteria
weresystematically included in the analysis in eachstratum until the
required number was achieved for each sub-stratum.
Ethical approval
Ethical approval for the study was obtained from KEMRI/
CDC, ethics review committee/institutional review board. Written
informed consent was obtained from each participant prior to
study initiation. Patients also consented for the use of their stored
samples for other future studies which included the reference
ranges analysis. Minors (,18 years of age) were classified as
‘‘mature’’ or ‘‘non-mature’’ using legal definitions. Mature minors
were married, a parent, or a head of household and could consent
to study participation as they would for HIV counseling and
testing in Kenya [30]. Non-mature minors went through a two-
step written consent process involving consent from the parent or
guardian followed by a private discussion with the minor that
included a thorough explanation of the study after which written
consent was obtained from those willing to participate.
Blood collection and HIV serology
Whole blood was collected in vacutainer tubes containing
EDTA (Becton Dickinson, Franklin Lakes, NJ) and transported to
the KEMRI/CDC HIV-research laboratory for processing and
analysis within six hours of specimen collection. The HIV status
was determined from whole blood using HIV rapid test kits as
follows: Determine (Abbot Laboratories, Tokyo, Japan), and
Unigold (Trinity Biotech Plc, Bray, Ireland), with Capillus (Trinity
Biotech Plc, Bray, Ireland) as a tie breaker.
Pregnancy testing
A urine pregnancy test was administered to all females of child-
bearing age, who were not visibly pregnant, using Randox, Inc.
latex monoclonal agglutination test (Antrim, Northern Ireland,
Reference Values for Adolescents and Adults
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South San Francisco, CA, USA).
Hematological analysis
Absolute white blood cell counts and percentages for leukocytes
(WBC) with differentials (neutrophils, lymphocytes, monocytes,
eosinophils, and basophils), erythrocytes (RBC) with parameters
(hemoglobin, hematocrit, MCV, and MCH), and platelet counts
were determined from whole blood using a Coulter ACT 5Diff CP
analyzer (Beckman Coulter, France). This was performed within
24 hours of sample collection as recommended by the manufacturer.
Flow cytometry analysis of lymphocyte subsets
Lymphocyte subsets were analyzed from whole blood on a
FACS calibur flow cytometer (Becton Dickinson, San Jose, CA)
with the following combinations of monoclonal antibodies (MAb):
anti-CD3-fluorescein isothiocyanate (FITC), anti-CD45-Peridinin
chlorophyll protein (PerCP), anti-CD4-Allophycocyanin (APC),
and anti-CD8-Phycoerythrin (PE) as per the manufacturer’s
recommendations. Staining was done within 12 hours of blood
collection. Analysis was done within 24 hours after staining and
the results were checked using the MultiSET software (Becton
Dickinson, San Jose, CA).
Biochemistry analysis
Clinical chemistries from serum samples were analyzed for
aspartate aminotransferase (AST), alanine aminotransferase
(ALT), total bilirubin (T-bil), glucose (Glu), creatinine (Cr), and
blood urea nitrogen (BUN) using the Cobas Integra 400 plus
biochemistry analyzer (Roche, Germany) per the manufacturer’s
instructions.
Quality Control
Quality control protocols included running known standards
each day before testing samples. In addition, the laboratory is
enrolled in external quality assurance testing programs with the
College of American Pathologists (lymphocyte immunophenotyp-
ing, hematology, and clinical chemistry) and the United Kingdom
National External Quality Assurance Service (lymphocyte immu-
nophenotyping).
Statistical analysis
Data were collected on optical character recognition (OCR)
enabled forms and entered with scanners. The data were then
grouped according to age (,18 years of age as adolescents and
$18 as adults) and gender, and analyzed using SAS v9.1 (Cary,
NC, USA). The normal distribution for each group was tested
using the Kolmogorov-Smirnov test that provided the median and
the 95
th percentile ranges. To eliminate bias due to small sample
size, a bootstrap analysis method was used as a robust method to
assess the 95% reference ranges from the Kolmogorov-Sminorv
test. For each parameter, 10,000 bootstrap samples were selected
and analyzed using SAS v9.1. [26,31] and the lower 95%
reference limit was defined as the 2.5 percentile while the upper
limit was defined at the 97.5 percentile.
A Wilcoxon rank-sum test was used to test for differences
between and within the two age groups. A two-sided P value of
,0.05 was considered significant. Box and whisker plots were also
plotted for parameters in which age variation existed to assess
distribution of these variations with age.
We then compared our data against reference intervals from the
Massachusetts General Hospital (MGH-USA) [24] and the U.S. NIH
Division of AIDS (DAIDS) toxicity tables [25] to determine the
number of study participants who had values outside the MGH ranges
or who had any adverse event as graded by the DAIDS criteria. The
Pearson chi-square test was used to compare the proportion of values
outside the MGH ranges by gender and age categories.
Results
A total of 2707 participants were enrolled in the two baseline
cross-sectional surveys. Of these 2307 were HIV-seronegative.
From these participants a total of two hundred and ninety eight
specimens from participants who met the eligibility criteria were
included in this study. One hundred and fifty four (51.7%) of these
were males while 144 (48.3%) were females. Almost half (46%) of
the study population were less than 18 years old, representing 77
(50%) of all males and 62 (47%) of all females.
Hematological Parameters
The mean, median and 95% reference values stratified by age
and gender, for different hematological parameters are presented
in Table 1.
Table 1. Hematological reference values (median and 95
th-percentile) stratified by age and gender from a 13–34 years old cohort
in rural western Kenya (2003–2005).
Age 13–17 years Age 18–34 years
Parameter Male (n=76) Female (n=57) Male (n=77) Female (n=83)
RBC (10
6 Cells/ml) 4.9 (4.1–5.8) 4.7 (3.3–5.4) 5.3 (4.3–6.5) 4.5 (3.4–5.7)
Hb (g/dL) 13.1(10.6–15.6) 12.2 (8.1–14.2) 14.2 (11.4–16.9) 12.1 (8.0–14.2)
HCT (%) 38.8 (29.3–48.1) 35.6 (24.8–43.1) 41.7 (32.6–51.5) 35.8 (23.2–44.3)
MCV (fL) 79 (62–92) 78 (57–91) 80 (55–98) 79 (60–94)
PLT (10
3 cells/ml) 224 (103–386) 233 (134–439) 201 (102–307) 220 (88–439)
WBC(10
3 cells/ml) 5.6 (3.3–8.3) 5.2 (3.9–10.2) 5.3 (2.5–7.4) 5.6 (3.3–9.7)
Ne (10
3 cells/ml) 1.9 (0.8–5.0) 2.0 (1.1–3.1) 2.0 (0.8–3.9) 2.3 (1.3–3.8)
Ly (10
3 cells/ml) 2.2 (1.0–4.2) 2.2 (1.1–3.1) 2.2 (1.0–3.5) 2.2 (1.3–3.8)
Mo (10
3 cells/ml) 0.5 (0.2–0.7) 0.4 (0.2–0.7) 0.5 (0.2–0.9) 0.5 (0.3–0.8)
Eo (10
3 cells/ml) 0.4 (0.1–1.8) 0.4 (0.1–2.2) 0.5 (0.1–1.7) 0.4 (0.1–1.3)
Ba (10
3 cells/ml) 0.04 (0.02–0.30) 0.04 (0–0.10) 0.04 (0.01–0.19) 0.04 (0–0.20)
doi:10.1371/journal.pone.0021040.t001
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observed statistically significant differences in RBC, HB and
HCT by gender, with males having higher values than females in
both age groups (Table 2).
We also observed differences in the hematological indices
among males by age, with the young adults having higher levels of
HB, HCT, RBC, and PLT as compared to adolescents P,0.001)
(Table 2). This variation was observed as a progressive increase
Table 2. Test of difference in hematologic, clinical chemistry and immunologic parameters between gender and age-groups from
the 13–34 years old rural western Kenya cohort (2003–2005).
Age 13–17 years Age 18–34 years
Parameter n median p-value (gender) n median p-value (gender)
P-value
(age)
Hemoglobin (g/dL)
Female 57 12.2 (8.1–14.2) ,.0001 83 12.1(8.0–14.2) ,.0001 0.3243
Male 76 13.1 (10.6–15.6) 77 14.2 (11.4–16.9) ,.0001
Hematocrit (%)
Female 57 35.6 (24.8–43.1) ,.0001 83 35.8 (23.2–44.3) ,.0001 0.8015
Male 76 38.8 (29.3–48.1) 77 41.7 (32.6–51.5) ,.0001
WBC (61000)
Female 57 5.2 (3.9–10.2) 0.6359 83 5.6 (3.3–9.7) 0.0189 0.2038
Male 76 5.6 (3.3–8.3) 77 5.3 (2.5–7.4) 0.6382
RBC (610
12/L)
Female 57 4.7 (3.3–5.4) 0.0001 83 4.5 (3.4–5.7) ,.0001 0.2638
Male 76 4.9 (4.1–5.8) 77 5.3 (4.3–6.5) ,.0001
Lymphocytes (610
9/L)
Female 57 2.2 (1.1–3.1) 0.9820 83 2.2 (1.3–3.8) 0.6901 0.9388
Male 76 2.2 (1.0–4.2) 77 2.2 (1.0–3.5) 0.585
Ab Neutrophiles (610
9/L)
Female 57 2.0 (1.0–6.2) 0.4991 83 2.3 (1.3–5.4) 0.0004 0.0576
Male 76 1.9 (0.8–5.0) 77 2.0 (0.8–3.9) 0.6575
PLT(610
9/L)
Female 57 233 (134–439) 0.2958 83 220 (88–439) 0.0222 0.4034
Male 76 224 (103–386) 77 201 (102–307) 0.0094
AST/SGOT (m/L)
Female 62 22.6 (12.0–43.1) 0.0102 82 22.2 (13.5–48.5) 0.0822 0.5905
Male 77 26.9 (17.0–59.2) 77 26.7 (12.5–69.3) 0.9147
ALT/SGPT (m/L)
Female 62 17.4 (4.2–65.3) 0.6289 82 18.9 (10.7–61.3) 0.2247 0.1305
Male 77 20.5 (4.9–42.4) 77 22.4 (12.0–80.6) 0.0901
Total Bilirubin (mmol/L)
Female 62 9.7 (3.7–38.5) 0.0331 82 11.5 (5.8–36.1) 0.0368 0.7132
Male 77 13.9 (5.7–62.6) 77 13.8 (5.3–50.7) 0.6662
Creatinine (mmol/L)
Female 62 64.5 (48.0–87.6) 0.0229 82 70.7 (52.4–96.8) ,.0001 0.0013
Male 77 66.3 (49.6–103.7) 77 83.1(54.2–137.8) ,.0001
CD4: Absolute
Female 58 934 (465–1553) 0.4074 83 866 (440–1602) 0.0141 0.509
Male 76 874 (367–1571) 77 811 (462–1306) 0.0209
CD8: Absolute
Female 58 506 (195–1068) 0.4506 83 472 (262–1167) 0.8706 0.9213
Male 76 468 (195–988) 77 468 (201–1104) 0.4194
CD4/CD8 ratio
Female 58 1.8 (0.9–3.2) 0.9215 83 1.8 (0.8–3.0) 0.0728 0.4879
Male 76 1.8 (0.8–2.8) 77 1.6 (0.8–2.8) 0.0543
doi:10.1371/journal.pone.0021040.t002
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whisker plots (Figure 1a & c). In comparison, there was little
variation in the same parameters among adolescents and adult
females (Figure 1b & d).
Platelet counts were significantly higher among young adult
females compared to the males in the same age group (P=0.0222)
and also differed between adolescent and young adult males
(P=0.0094) (Table 2). The median and 95th percentile values for
absolute and WBC subsets (neutrophils, lymphocytes, monocytes,
eosinophils and basophils) stratified by both age and genders are
shown in Table 1. No gender or age differences were observed in
absolute lymphocytes, basophil, eosinophil and monocytes counts.
There were significant differences in neutrophil counts between
male and female young adults, with the females having higher
counts than males (Table 2).
Comparison with MGH and other African cohort-derived
values. Our hematological parameters showed significant
differences from the MGH US-population-derived values (Table 3).
A higher proportion of our study participants (22.5–35%) had WBC,
neutrophil, HB, HCT and platelet counts that were outside the lower
range of MGH US population-derived values. Eosinophil values,
however, were significantly higher, and the upper range in our study
Figure 1. Box and whisker plots showing variation in hematological values with age and gender. Hemoglobin (A and B) and Red Blood
Cell count (C and D) variation with age in both males (left panel) and females (right panel) from rural western Kenya.
doi:10.1371/journal.pone.0021040.g001
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between age and gender with no statistically significant difference
except for hemoglobin, where the younger population had slightly
more out-of-range values (OOR) (53%) than the older group (34%).
Comparing these values with those obtained from neighboring
regions, the lower and upper limits for the hematological ranges
obtained from this population were slightly lower than those
derived from the Uganda, Tanzania and Ethiopia cohorts but
were higher than those reported from the Kericho-Kenyan cohort,
a region neighboring this study population (Table 4). However,
age-specific data were not available for the comparison reference
intervals.
Immunological parameters
The mean, median and 95% reference values stratified by age
and gender, for absolute and percentage CD4 and CD8 as well as
the ratios are presented in Table 5.
Differences between gender and age groups. Analyses of
lymphocyte subsets indicated minimal differences between both
gender and age groups, with the exception of CD4 indices. In both
age groups, females had higher percentage and absolute CD4 cell
count than males, the difference being significant only in the older
age group. In assessing age variability, younger age was associated
with higher CD4 cell counts and a higher CD4:CD8 ratio, the
difference being significantly higher in males (especially for CD4
counts) (Table 2).
Comparison with the US and other African cohort derived
values. In comparing the upper and lower reference values
from this population to the US-derived machine reference values,
the CD4 cell counts were similar with only 2% being out of range
(Table 3). Moreover, the upper limits of our overall CD4 cell
counts closely compared with those reported from Mbeya in
Tanzania, Kampala in Uganda and Kericho in Kenya (Table 4).
Clinical Chemistry Parameters
The mean, median and 95% reference values stratified by age
and gender, for clinical chemistry parameters are presented in
Table 6.
Differences between gender and age groups. Analyses of
liver and kidney function tests indicated gender and age variations
between young adults and adolescents. Males had higher values
for ALT, AST, T-bil and creatinine than females in both age
groups, with those differences being significantly greater for T-bil
and creatinine indices in both age-groups and AST among the
Table 3. Out of range and frequency of adverse events in the rural western Kenyan cohort obtained from comparison with values
from DAIDS and North American derived MGH values.
out of range Comparison Division of AIDS toxicity grading (DAIDS) [26]
Grade 1 Grade 2 Grade 3 Grade 4
Parameter n Units
Study
Reference
intervals USA [25] n % n % n % n % n %
Hemoglobin Males 140 g/dl 10.8–16.1 13.5–17.5 65 46 2 1.3 0 0 2 1.3 0 0
Hemoglobin Females 153 g/dl 8.0–14.2 12–16 61 40 11 7.9 8 5.7 14 10 0 0
Hct (females) 140 % 23.2–44.2 36–46 74 53
Hct (males) 153 % 29.4–49.3 41–53 88 58
RBC (males) 140 610‘6 cells/ml 4.2–6.3 4.5–5.9 29 19
RBC (females) 153 610‘6 cells/ml 3.3–5.6 4.0–5.2 32 23
MCV 293 fL 60–93 80–100 157 54
Platelets 293 610‘3 cells/ml 103–390 150–350 53 18 6 2 6 2 0 0 0 0
WBC 293 610‘3 cells/ml 3.3–9.3 4.5–11.0 66 23 2 0.7 0 0 0 0 0 0
Lymphocyte count 293 610‘3 cells/ml 1.1–3.5 1.0–4.8 6 2 0 0 0 0 0 0 0 0
Neutrophil count 293 610‘3 cells/ml 0.9–5.2 1.8–7.7 110 38 25 8.5 9 3.1 1 0.3 0 0
Eosinophil 293 610‘3 cells/ml 0.1–1.7 0–0.5 130 44 60 20.5 12 4.1 0 0 0 0
Basophil count 293 610‘3 cells/ml 0.02–0.18 0–0.2 5 2
Monocyte count 293 610‘3 cells/ml 0.2–0.8 0–0.8 0 0
ALT (SGPT) 293 IU/ml 7.2–61.3 0–35 30 10 12 4.1 1 0.3 0 0 0 0
AST (SGOT) 293 IU/ml 13.8–50.4 0–35 40 13 9 3.1 3 1 0 0 0 0
Total Bilirubin 293 ml mol/L 5.1–40.7 5.1–17.0 90 30 37 12.7 27 9.2 4 1.4 1 0.3
Creatinine 293 ml mol/L 50–113 0–133 4 1 4 1.4 0 0 0 0 0 0
Glucose 293 mmol/L 2.1–6.6 4.2–6.4 210 72
BUN 293 mmol/L 1.2–5.1 3.6–7.1 246 84
*CD4 293 Cells/ml 444–1488 404–1612 6 2 3 1 1 0.3 0 0 0 0
*CD8 293 Cells/ml 211–1078 220–1129 13 4
*Reference ranges provided by Becton-Dickinson with the MultiTEST IMK Kit Reagent package (12/2000;23-3602-02).
-DAIDS- Division of AIDS tables for grading the severity of adult and pediatric adverse events [26].
- MGH-Massachusetts General Hospital weekly case records [25].
doi:10.1371/journal.pone.0021040.t003
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nitrogen and glucose levels for all age groups and no significant
differences in T-bil, AST, ALT and glucose between the two age
groups for both males and females. However young adult men and
women did have higher values for creatinine and blood urea
nitrogen compared to adolescent males and females, respectively.
Comparison with MGH and other African cohort derived
values. Our chemistry reference intervals differed with the US
Table 4. Hematological and Biochemistry Laboratory reference ranges derived from rural Western Kenya compared to other
sources in Africa.
Parameter Western-Kenya
Kericho-
Kenya
(2008) [6]
Uganda
(2008) [47]
Tanzania
(2008) [23]
Ethiopia
(1999) [22]
Combined study from
Kenya, Uganda, Zambia
and Rwanda (2009) [37]
Hemoglobin (g/dL)
Male 10.8–16.1 8.3–11.3 11.6–17.1 13.7–17.7 13.9–18.3 12.2–17.0
Female 8.0–14.2 5.9–10.0 9.8–16.2 11.1–15.7 12.2–16.1 9.5–15.8
Hematocrit (%)
Male 29.4–49.3 40–50 33.8–49.5 40.2–53.7 41.6–55.1 35.0–50.8
Female 23.20–44.2 30–50 28.3–46.8 36.2–46.8 35.3–48.8 29.4–45.4
RBC’s (10‘6 cells/ml)
Male 4.2–6.3 4.4–6.3 3.8–6.1 4.4–6.3 4.3–5.9 4.0–6.4
Female 3.3–5.6 3.7–5.6 3.3–5.3 3.8–5.6 3.7–5.2 3.8–5.6
Platelets (10‘6 cells/ml) 103–390 120–411 109–384 150–395 N/A 126–438
MCV (fl) 60–93 68.8–97.2 71–97 77.6–98.1 N/A 68–98
WBC (10‘6 cells/ml) 3.3–9.3 2.8–8.2 2.8–8.2 2.7–8.3 3.0–10.2 3.1–9.1
Neutrophils (10‘3 cells/ml) 0.9–5.2 0.9–4.7 0.9–3.9 1.1–4.7 N/A 1.0–5.3
Lymphocytes (10‘3 cells/ml) 1.1–3.5 1.1–3.5 1.2–3.7 1.1–3.0 N/A 1.2–3.7
Monocytes (10‘3 cells/ml) 0.2–0.8 0.1–0.6 0.2–0.7 N/A N/A 0.2–0.78
Eosinophils (10‘3 cells/ml) 0.1–1.7 0.03–1.1 0.04–1.60 N/A N/A 0.04–1.53
Basophils (10‘3 cells/ml) 0.02–0.18 0.01–0.08 0.01–0.08 N/A N/A 0.01–0.15
CD4 (Cells/ml) 444–1488 421–1550 N/A 406–1392 366–1235 457–1628
CD8 (Cells/ml) 211–1078 210–1081 N/A 188–990 311–1618 230–1178
CD4:CD8 0.8–3.0 0.9–3.3 N/A 0.8–3.2 0.4–2.4 N/A
Chemistries
ALT (IU/ml) 7.2–61.3 8.6–47.0 6.6–42.8 0–48.8 __ 8–61
AST (IU/ml) 13.8–50.4 13.1–45.3 12.3–34.8 0–48 __ 14–60
T-Bil (ml mol/L) 5.1–40.7 4.4–41.9 __ 5.2–41 __ 2.9–37
Creatinine (ml mol/L) 50–1488 __ __ __ __
Male 52–125 62–106 __ __ __ 47–109
female 49–97 51–91 __ __ __ 47–109
Glucose (mmol/L) 2.1–6.6 3.1–5.7 N/A 2.9–5.2 __ N/A
doi:10.1371/journal.pone.0021040.t004
Table 5. Lymphocyte sub-sets reference ranges (median and 95
th-percentile) from a cohort (13–34 years) in rural Western Kenya
(2003–2005).
Age 13–17 years Age 18–34 years
Parameter Male (n=76) Female (n=58) Male (n=77) Female (n=83)
CD4 (10
3 cells/mm
3) 874 (367–1571) 934 (465–1553) 811 (462–1306) 866 (440–1602)
CD8(10
3 cells/mm
3) 468 (196–988) 505 (195–1068) 486 (201–1104) 472 (262–1167)
CD4 % 42 (32–56) 44 (30–56) 41 (29–54) 44 (32–55)
CD8 % 23.1(12.4–36.4) 23.5 (17.0–34.8) 24.6 (14.9–44.0) 24.3 (17.5–35.0)
CD4:CD8 ratio 1.8 (1.0–3.1) 1.8 (0.9–3.2) 1.6 (0.8–2.8) 1.8 (0.8–2.8)
doi:10.1371/journal.pone.0021040.t005
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participants with OOR values for BUN, glucose and T-bil which
were 84%, 72% and 30% respectively (Table 3). There were no
significant differences in the distribution of OOR values by age.
Our values were comparable with those reported in other African
cohorts, although our upper values for ALT and creatinine were
higher than the other published studies (Table 4).
Classification of Adverse Events using US-derived DAIDS
Grading Criteria
Applying our data to the classification of adverse events using the
DAIDS grading criteria for 11 of the indices in our study, over 40%
of our otherwise healthy study participants would have erroneously
been considered to have at least one laboratory-based grade 1–4
toxicity adverse event (AE) (Table 3). Values for eosinophil and
neutrophil counts, HB, and LFT resulted in a majority of abnormal
classifications. The high eosinophil counts observed would have led
to 60 (20.5%) participants being classified as grade 1 and 12 (4.1%)
as grade 2. Low HB levels among our participants would have
resulted in 37 reported AEs; 13 (4.4%) as grade 1, 8 (2.7%) as grade
2 and 16 (5.5%) as grade 3. Low neutrophil counts would have
resulted in 35 AE cases: 25 as grade 1 (8.5%), 9 (3.1%) as grade 2
and 1 as grade 3 (0.3%). The chemistry analytes also differed with
the US-based values, especially for T-bil, where 68 participants
would have been classified as having toxicity levels of grade 1 or
above; 37 (12.7%) as grade 1, 27 (9.2%) as grade 2 and 4 as grade 3
(1.4%). DAIDSgradingofourASTandALTlevels would alsohave
classified a total of 25 grade 1–4 toxicity events with12 (4.1%) and 9
(3.1%) as grade 1 and 1 (0.3%) and 3 as grade 2 (1.0%) for ALT and
AST, respectively.
Discussion
Clinical laboratory values provide important data to help assess
the health of an individual. For this reason they are routinely used
in clinical trials at enrollment and also during the course of the
trial for monitoring the participants’ health. Moreover, several
analytes are used either as surrogate markers for indicating the
possible presence of a disease or as direct evidence for that disease
[32–34]. In the absence of locally derived reference values for
African populations, clinicians and researchers have had to use
reference values of European or North American populations.
Previous studies have shown that such values vary with age, ethnic
origin, socio-demographic characteristics, and environmental
context [6,8,9,21,35–37]. The development of region and age-
specific reference values is thus essential for efficient patient
management and proper conduct of clinical research. This is
especially critical for clinical trials being conducted in Africa to
reduce the burden of such diseases as malaria, TB, and HIV in this
region. Apart from their use in clinical trials, some laboratory
markers are HIV disease surrogate markers and are thus
important in care and treatment of HIV-infected patients in sub-
Saharan Africa that has the greatest burden of the pandemic [4–
6]. Our study was carried out in Nyanza Province, western Kenya,
the region with the highest HIV prevalence in Kenya (15%) [38].
It is also the region in Kenya where many clinical research studies
are being carried out [39–41]. Most of the values observed in this
population differed with standard US-based reference values
(MGH/DAIDS).
Regarding hematological indices, most of our values were lower
than those derived from North American population; this finding is
consistent with previous studies in other African regions [8,21,22].
However, our combined values for HB and MCV for both young
adults and adolescents were higher than those reported from
another study in Kericho, Kenya [6], but were slightly lower than
those derived from Ethiopia, Kampala in Uganda and Mbeya in
Tanzania [8,21,22]. The findings of significant genderdifferences in
RBC parameters (RBC, HB, HCT, and MCV) are consistent with
previously established evidence that men have higher values than
females for these parameters. This difference is partly attributed to
the influence of the androgen hormone on erythropoiesis [42,43]
and to menstrual blood loss in women [6,8,20,21,44]. As previously
reported in other studies targeting adolescents [15,20], older males
from this population had significant higher values for RBC, HB and
HCT than young males. The difference could be attributed to
higher levels of androgen hormones among the older as compared
to the younger males. This potential explanation is further
supported by the absence of age-related hematological difference
among females in our study, which is in agreement with findings
obtained from previous studies targeting adolescent cohorts [15].
The lower platelet counts from this population as compared to
Western values are synonymous with findings from other African
studies [7,8,11,22,45]. The etiology of low platelet counts in
African populations is unknown. However dietary, environmental
and genetic factors have been proposed [7,11,45]. In agreement
with other African studies [6,8,28,35,46] was the high eosinophil
and low WBC and neutrophil values compared to those in North
America. The eosinophilia may be attributed to increased
parasitemia, since our study area is endemic for schistosomiasis,
helminthic infections and perennial malaria [27,28]. The low
neutrophil count observed in our population could possibly be
attributed to African genetics, environment or diet [36,46].
The differences in gender and age in both WBC and CD4 cell
counts are in agreement with previous reports [8,14]. Females
generally had higher counts, while young adolescents had equally
higher values for both WBC and CD4 cell count as compared to
adults. Overall our ranges for the lymphocyte subsets were higher
and comparable to the USA reference ranges. The mean CD4 cell
count for our population was 857.9, which is consistent with mean
CD4 cell counts reported in other HIV-negative populations in
Africa.
Liver and renal function tests are also important indicators of
patient response to ARTs in the management of HIV/AIDS
patients. Clinical chemistry laboratory reference values for LFT
and renal function tests are limited in Africa, despite the
continuous use of ARTs in this region. Most of our clinical
chemistry reference ranges were comparable with the US MGH
ranges except for T-bil and blood urea nitrogen. As seen from
other studies conducted in Kenya [6], Uganda [8] and Tanzania
[21] the upper range for T-bil seen in this study was twice as high
as that of the US while the lower range for BUN was twice as low.
The etiology of high T-bil in this population is thought to arise
from a number of factors like RBC hemolysis caused by malaria or
sickle cell disease, malnutrition or physical exertion. However the
presence of similar trends among other African populations is
suggestive of a common environmental or genetic factor [6,37].
Analysis of the comparison between the values obtained from
this population with those from the MGH ranges used in most
clinical research studies revealed high variations for most values. If
the US MGH derived ranges were used on this population during
screening for any clinical research, over 58% of the volunteers
would be screened out of the trial despite having laboratory results
consistent with the general population. This erroneous screening
would have important implications on study cost, work load and
time, as more volunteers would be required for the screening
process to meet the required target, even though the screening out
process would actually have excluded healthy potential volunteers
[47]. Moreover, the fact that the investigational product is
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values differ with the values being used at the screening process
might further complicate post-market analysis or adoption of the
product for the general population.
Equally important is the comparison to the DAIDS toxicity tables;
some of the ranges obtained extend between the normal and grade 1–
2 toxicity grading. The lower range for HB (8.0 in females), neutrophil
counts (0.9), as well as the upper range for eosinophil counts (1.68) and
T-bil (40.7) would have been considered as grade 2 adverse events. In
addition the observed lower ranges in males for HB (10.8) and the
combined values for ALT (61.3) and AST (50.4) would have been
classified as grade 1 adverse event. The use of the DAIDS toxicity
grading for such populations may lead to inappropriate reporting of
adverse events during clinical trials.
In agreement with other published data, we observed age-related
variation between the adolescent males as compared to the adults
for HB, HCT and RBC levels [8,15,20]. The fact that adolescents
had lower hematological values is an issue that should be noted
whenever clinical trials target this population. However, the
observed differences may not be of medical significance, and thus
there is need for further research as participation of adolescents in
clinical trials increases. Weobserved nosignificantagedifferences in
other parameters measured among males or in any parameters
measured in females except for creatinine and BUN. This implies
that adult values can be used in clinical trials involving adolescents
for such parameters for which no differences were reported.
Several limitations could be cited in our study. Clinical
Laboratory and Standards Institute (CLSI) guidelines for labora-
tory indicators recommend the consideration of genetic, environ-
mental and social habits (such as smoking, dietary components,
exercise and lifestyle) for which data were not obtained during
enrollment of the participants in this study [11,35,37,48]. The
sample size was also small in the two age sets and did not meet the
recommended CLSI sample size of 120 per every partitioned
group [48]. However, a robust bootstrap analysis was used so as to
eliminate bias as recommended by the Canadian laboratory
initiative on paediatric reference intervals (CALIPER) [49]. In
addition, although a thorough medical examination was done, not
all sub-clinical conditions such as parasitic infections, hepatitis B
infection or nutrition factors known to interfere with the obtained
parameters were assessed. However, in the context of resource-
limited settings, we assert that our study methods were sufficient to
determine reference ranges for use in this population.
The findings from our study confirmed previously published
data documenting differences in clinical laboratory reference
ranges between African and Western populations. We also assert
that there exist age variations in hematological values among
males that reinforce the need to establish age-specific reference
ranges for use in clinical trials involving such a population. This
study presents the first description of biochemistry and hemato-
logical reference ranges in western Kenya, and is also the first
study in the country that compares two distinct age sets between
adolescents and adults. The development of these reference ranges
may provide guidelines to be used by local health practioners in
patient management within this region and for the design, conduct
and evaluation of clinical trials for biomedical interventions.
Whilst our study limitations may have influenced the different
study parameters, our findings were comparable to those of other
studies within Africa [6,22,23,37,47] and can be used as reference
ranges for adolescents and young adults within Kenya.
As clinical trials and anti-retroviral treatment increase in Africa,
locally derived clinical laboratory reference ranges are essential to
ensure appropriate treatment monitoring, general health assessment
and efficient execution of clinical trials. Similarly important is the
need for development of toxicity grades for use among African
populace in clinical care based on the differences observed between
laboratory values from African population and the West. So far
clinical studies as well as routine clinical patient management in most
African countries are using either the European generated machine
values, or the NIH division of AIDS toxicity grading in assessing
critical values. The development of the various laboratory-derived
African toxicity grades, in addition to the already developed reference
values would thus be ideal for use in reporting adverse events in
clinical trials as well as in routine health care for determining critical
values. Using Western-derived reference ranges, a majority of our
study participants would have been misclassified due to the high
eosinophil counts and T-Bil as a consequence of regular exposure to
endemic pathogens and inherent genetic factors leading to
unnecessary treatment. Thus, physicians need to take into consider-
ation the population limitations while attending to patients within this
region. This study provides the first age-specific, locally derived
clinicallaboratoryreferenceranges inwesternKenya for use inhealth
care and clinical research.
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Table 6. Clinical Chemistries Medians and 95% Reference Intervals stratified by age and gender from a 13–34 years cohort study in
rural western Kenya (2003–2005).
Age 13–17 years Age 18–34 years
Parameter Male (n=77) Female (n=62) Male (n=77) Female (n=82)
ALT (U/L) 20.5 (4.9–42.4) 17.4 (4.2–65.3) 22.4 (12.0–80.6) 18.9 (10.7–61.3)
AST (U/L) 26.9 (17.0–59.2) 22.6 (12.0–43.1) 26.7 (12.5–69.3) 22.2 (13.5–48.5)
T-Bil (umol/L) 13.9 (5.7–62.6) 9.7 (3.7–38.5) 13.8 (5.3–50.7) 11.5 (5.8–36.1)
Creatinine (umol/L) 66.3 (49.6–103.7) 64.5 (48.0–87.6) 83.1 (54.2–137.8) 70.7 (52.4–96.8)
Glu (mmol/L) 3.8 (2.2–6.6) 3.8 (2.0–7.0) 3.7 (2.1–9.0) 3.8 (2.1–6.0)
BUN (mmol/L) 2.5 (1.7–4.1) 2.3 (1.2–4.8) 3.0 (1.8–5.3) 2.8 (1.4–4.5)
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